| Mark Meranda, RPH | |
|
885 Calico Ct, Waukesha, WI 53186-2302 | |
| (262) 717-9440 | |
| (262) 717-9441 |
| Full Name | Mark Meranda |
|---|---|
| Gender | Male |
| Speciality | Pharmacist |
| Location | 885 Calico Ct, Waukesha, Wisconsin |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1184621070 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 11247 (Wisconsin) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mark Meranda, RPH 885 Calico Ct, Waukesha, WI 53186-2302 Ph: (262) 717-9440 | Mark Meranda, RPH 885 Calico Ct, Waukesha, WI 53186-2302 Ph: (262) 717-9440 |
News Archive
The Stanford University Program in Biodesign is partnering with the government of India to establish a new training program, called Stanford-India Biodesign, to help create the next generation of biomedical technology innovators in India.
New guidelines developed by the American Academy of Neurology confirm that the drug botulinum toxin is safe and effective for treating cervical dystonia, a condition of involuntary head tilt or neck movement, spasticity and other forms of muscle overactivity that interfere with movement in adults and children with an upper motor neuron syndrome, and excessive sweating of the armpits and hands.
Fresenius Medical Care, the world's leading provider of dialysis products and services, announced the further enhancement of support for home dialysis patients in Western Australia.
Cell Therapeutics, Inc. announced today that the April 2011 edition of the peer reviewed journal, Leukemia & Lymphoma published results of a phase I/II clinical trial evaluating the effect of cyclophosphamide, pixantrone, vincristine, and prednisone in treating patients with aggressive non-Hodgkin's lymphoma who relapsed following initial therapy with cyclophosphamide, doxorubicin, vincristine, and prednisone.
After identifying three different types of resistance to a promising investigational lung cancer drug in a phase 1 trial, a team of researchers led by Dana-Farber Cancer Institute scientists say new targeted inhibitors and combinations are urgently needed to stay ahead of tumors' constant and varied molecular shape-shifting.
› Verified 6 days ago
Emma Holmi, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 801 E Sunset Dr, Waukesha, WI 53189 Phone: 262-899-6010 Fax: 262-542-1965 | |
Peter Michael Stachnik, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 601 Meadowbrook Rd, Waukesha, WI 53188 Phone: 262-549-2356 | |
Dr. Matthew Schendel, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1535 E Moreland Blvd, Waukesha, WI 53186 Phone: 262-896-6767 Fax: 262-896-6794 | |
Dr. Sara Anne Erdahl, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: N16w24131 Riverwood Dr, Waukesha, WI 53188 Phone: 262-696-5685 | |
Mrs. Julie Ann Wells, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 230 Madison St, Waukesha, WI 53188 Phone: 262-542-9935 | |
Dr. Amanda Anne Sullivan, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 801 E Sunset Dr, Waukesha, WI 53189 Phone: 262-899-6010 | |
Susan R Hanosh, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 221 E Sunset Dr, Waukesha, WI 53189 Phone: 262-542-3981 |